Physician profile
Brian James Thacker
NPI 1275037145
$4,587.64
in general payments reported to CMS, 2019-2025
36 companies · $844 in 2025
The $844 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $1,279 · 2023: $907 · 2024: $1,231 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,981.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $660.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $462.19 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.79 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $305.72 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $289.21 | 2022-2025 | |
| Glaxosmithkline, LLC. | $256.10 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $233.67 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $219.37 | 2022-2025 | |
| Amgen INC. | $212.28 | 2022-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $187.40 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $184.38 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $154.22 | 2021-2022 | |
| Exact Sciences Corporation | $121.53 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $111.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $107.28 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $97.72 | 2024-2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $77.45 | 2021-2022 | |
| Mylan Specialty L.P. | $51.11 | 2022-2023 | Yupelri |
| Nevro Corp. | $50.70 | 2023 | Senza |
| Philips North America LLC | $41.80 | 2023-2025 | Ecc Solutions |
| Daiichi Sankyo INC. | $40.92 | 2021-2025 | Injectafer |
| Hologic Sales and Service, LLC | $32.42 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Xeris Pharmaceuticals, INC. | $27.71 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $27.60 | 2022-2023 | Eliquis |
| Organon LLC | $25.84 | 2025 | Nexplanon |
| Insulet Corporation | $24.64 | 2024 | Omnipod |
| Sumitomo Pharma America, INC. | $21.05 | 2023 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $20.46 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.73 | 2024 | Quviviq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.05 | 2022 | |
| Ardelyx, INC. | $15.66 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $14.78 | 2022 | |
| Merck Sharp & Dohme LLC | $13.75 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $13.55 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $12.98 | 2021 | |
| Sanofi Pasteur INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.